PEGylation technology in nanomedicine

Advances in Polymer Science

Volumn 247, Issue 1, 2012, Pages 115-140

  Ikeda, Yutaka ^a   Nagasaki, Yukio ^a,b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Drug delivery; Nanomedicine; Nanoparticle; PEGylated drug; PEGylation

Indexed keywords

EID: 84858120390     PISSN: 00653195     EISSN: None     Source Type: Book Series    
DOI: 10.1007/12_2011_154     Document Type: Review

References (82)

1. Abuchowski A, van Es T, Palczuk NC, Davis FF (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578-3581 (Pubitemid 8116087)
2. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252:3582-3586 (Pubitemid 8116088)
3. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459-476 (Pubitemid 34615543)
4. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D (2006) Structure-function engineering of interferonbeta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17:618-630 (Pubitemid 43794371)
5. Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S (2007) Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem 18:61-76 (Pubitemid 46145995)
6. Brocchini S, Godwin A, Balan S, Choi JW, Zloh M, Shaunak S (2008) Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev 60:3-12 (Pubitemid 350181163)
7. Wong SS (1991) Chemistry of Protein Conjugation and Cross-linking. CRC Press, Boston
8. Hu J, Sebald W (2011) N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH. Int J Pharm 413:140-146
9. Lee H, Jang IH, Ryu SH, Park TG (2003) N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 20:818-825 (Pubitemid 36515317)
10. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 23:175-186
11. Sato H (2002) Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54:487-504 (Pubitemid 34615545)
12. Lorand L, Parameswaran KN, Stenberg P, Tong YS, Velasco PT, Jönsson NA, Mikiver L, Moses P (1979) Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry 18:1756-1765 (Pubitemid 9190403)
13. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature's biological glues. Biochem J 368:377-396 (Pubitemid 35454517)
14. Fontana A, Spolaore B, Mero A, Veronese FM (2008) Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60:13-28 (Pubitemid 350181164)
15. Otsuka H, Nagasaki Y, Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55:403-419 (Pubitemid 36293792)
16. Nagasaki Y, Iijima M, Kato M, Kataoka K (1995) Primary amino-terminal heterobifunctional poly(ethylene oxide). Facile synthesis of poly(ethylene oxide) with a primary amino group at one end and a hydroxyl group at the other end. Bioconjug Chem 6:702-704
17. Nagasaki Y, Kutsuna T, Iijima M, Kato M, Kataoka K, Kitano S, Kadoma Y (1995) Formylended heterobifunctional poly(ethylene oxide): synthesis of poly(ethylene oxide) with a formyl group at one end and a hydroxyl group at the other end. Bioconjug Chem 6:231-233
18. Akiyama Y, Nagasaki Y, Kataoka K (2004) Synthesis of heterotelechelic poly(ethylene glycol) derivatives having alpha-benzaldehyde and omega-pyridyl disulfide groups by ring opening polymerization of ethylene oxide using 4-(diethoxymethyl)benzyl alkoxide as a novel initiator. Bioconjug Chem 15:424-427 (Pubitemid 38365205)
19. Akiyama Y, Otsuka H, Nagasaki Y, Kato M, Kataoka K (2000) Selective synthesis of heterobifunctional poly(ethylene glycol) derivatives containing both mercapto and acetal terminals. Bioconjug Chem 11:947-950.
20. Hiki S, Kataoka K (2007) A facile synthesis of azido-terminated heterobifunctional poly (ethylene glycol)s for "click" conjugation. Bioconjug Chem 18:2191-2196 (Pubitemid 350220024)
21. Hiki S, Kataoka K (2010) Versatile and selective synthesis of "click chemistry" compatible heterobifunctional poly(ethylene glycol)s possessing azide and alkyne functionalities. Bioconjug Chem 21:248-254
22. Pasut G, Veronese FM (2007) Polymer-drug conjugation, recent achievements and general strategies. Progr Polym Sci 32:933-961 (Pubitemid 47198290)
23. Zhao H, Yang K, Martinez A, Basu A, Chintala R, Liu HC, Janjua A, Wang M, Filpula D (2006) Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono-and multi-PEGylated proteins. Bioconjug Chem 17:341-351
24. Veronese FM, Caliceti P, Schiavon O (1997) Branched and linear poly(ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic and immunological properties of proteinconjugates. J Bioact Compatible Polym 12:196-207 (Pubitemid 27470395)
25. Aghemo A, Rumi MG, Colombo M (2010) Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 7:485-494
26. Campa C, Harding SP (2011) Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12:173-181
27. Patel AM, Moreland LW (2010) Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol 6:855-866
28. Fee CJ (2007) Size comparison between proteins PEGylated with branched and linear poly (ethylene glycol) molecules. Biotechnol Bioeng 98:725-731 (Pubitemid 350032676)
29. Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J,Wu G, Kneller S, Davies J, Duncan R (2005) PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 16:775-784 (Pubitemid 41026163)
30. Pinholt C, Bukrinsky JT, Hostrup S, Frokjaer S, Norde W, Jorgensen L (2011) Influence of PEGylation with linear and branched PEG chains on the adsorption of glucagon to hydrophobic surfaces. Eur J Pharm Biopharm 77:139-147
31. Somack R, Saifer MG, Williams LD (1991) Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 daltons). Free Radic Res Commun 12-13:553-562
32. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV (1988) Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263:15064-15070
33. Brandenberger C, Mühlfeld C, Ali Z, Lenz AG, Schmid O, Parak WJ, Gehr P, Rothen-Rutishauser B (2010) Quantitative evaluation of cellular uptake and trafficking of plain and polyethylene glycol-coated gold nanoparticles. Small 6:1669-1678
34. Robers MJ, Harris JM (1998) Attachment of degradable Poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm sci 11:1440-1445 (Pubitemid 28514154)
35. Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y (2004) Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 47:4897-4904 (Pubitemid 39238265)
36. Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK (1999) New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10:703-707 (Pubitemid 29456355)
37. Filpula D, Zhao H (2008) Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 60:29-49 (Pubitemid 350181165)
38. Yatuv R, Robinson M, Dayan I, Baru M (2010) Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv 7:187-201
39. Hatakeyama H, Akita H, Harashima H (2011) A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63:152-160.
40. Ishida T, Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354:56-62
41. Xu H, Wang KQ, Deng YH, da Chen W (2010) Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31:4757-4763
42. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H (2011) Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32:4306-4016
43. Kubetzko S, Sarkar CA, Plückthun A (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68:1439-1454 (Pubitemid 41540000)
44. Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83:601-606 (Pubitemid 24222392)
45. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780-783 (Pubitemid 29365106)
46. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A (2006) PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 281:35186-35201 (Pubitemid 46043248)
47. Andresen H, Bier FF (2009) Peptide microarrays for serum antibody diagnostics. Methods Mol Biol 509:123-134
48. Yoshimoto K, Nishio M, Sugasawa H, Nagasaki Y (2010) Direct observation of adsorptioninduced inactivation of antibody fragments surrounded by mixed-PEG layer on a gold surface. J Am Chem Soc 132:7982-7989
49. Uchida K, Otsuka H, Kaneko M, Kataoka K, Nagasaki Y (2005) A reactive poly(ethylene glycol) layer to achieve specific surface plasmon resonance sensing with a high S/N ratio: the substantial role of a short underbrushed PEG layer in minimizing nonspecific adsorption. Anal Chem 77:1075-1080 (Pubitemid 40261775)
50. Yu D, Peng P, Dharap SS, Wang Y, Mehlig M, Chandna P, Zhao H, Filpula D, Yang K, Borowski V, Borchard G, Zhang Z, Minko T (2005) Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. J Control Release 110:90-102 (Pubitemid 41713934)
51. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-259 (Pubitemid 27429892)
52. Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, Martinez A, Gao Y, Lozanguiez Y, Longley C, Greenberger LM, Horak ID (2008) Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 19:849-859 (Pubitemid 351614540)
53. Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID, Ponzoni M (2010) Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 16:4809-4821
54. Hershfield MS (1995) PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 5:107-112
55. Burns CM, Wortmann RL (2011) Gout therapeutics: new drugs for an old disease. Lancet 377:165-177
56. Laden JC, Philibert P, Torreilles F, Pugnière M, Martineau P (2002) Expression and folding of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. Res Microbiol 153:469-474 (Pubitemid 35245374)
57. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981 (Pubitemid 46202317)
58. Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC (2007) Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 13:7113-7118 (Pubitemid 350276896)
59. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12:329-340
60. Lares MR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28:570-579
61. Joralemon MJ, McRae S, Emrick T (2010) PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb) 46:1377-1393
62. Tamura M, Ichinohe S, Tamura A, Ikeda Y, Nagasaki Y (2011) In vivo and in vitro characteristics of core-shell-type nanogel particles: optimization of core cross-linking density and surface PEG density in PEGylated nanogels. Acta Biomaterialia. doi:10.1016/j. actbio.2011.05.027
63. Oishi M, Nagasaki Y (2010) Stimuli-responsive smart nanogels for cancer diagnostics and therapy. Nanomedicine (Lond) 5:451-468
64. Elbayoumi TA, Torchilin VP (2008) Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 5:1185-1198
65. Jiang W, Lionberger R, Yu LX (2011) In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3:333-344
66. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160 (Pubitemid 40282557)
67. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237 (Pubitemid 20233874)
68. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K (1991) Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51:3229-3236
69. Alakhov V, Klinski E, Lemieux P, Pietrzynski G, Kabanov A (2001) Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Expert Opin Biol Ther 1:583-602 (Pubitemid 33769072)
70. Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agentincorporating polymer micelles. Cancer Sci 100:572-579
71. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977-8983 (Pubitemid 38064079)
72. Bae Y, Kataoka K (2009) Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev 61:768-784
73. Karakoti AS, Das S, Thevuthasan S, Seal S (2011) PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl 50:1980-1994
74. Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132:4678-4684
75. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA (2006) Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312:1027-1030
76. Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, Bischof JC (2006) Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factoralpha delivery. Mol Cancer Ther 5:1014-1020 (Pubitemid 43724602)
77. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N, Tamarkin L (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139-149
78. Ishii T, Otsuka H, Kataoka K, Nagasaki Y (2004) Preparation of functionally Pegylated gold nanoparticles with narrow distribution through autoreduction of auric cation by alphabiotinyl-PEG-block-[poly (2-(N, N-dimethylamino) ethyl methacrylate)]. Langmuir 20:561-564
79. Miyamoto D, Oishi M, Kojima K, Yoshimoto K, Nagasaki Y (2008) Completely dispersible PEGylated gold nanoparticles under physiological conditions: modification of gold nanoparticles with precisely controlled PEG-b-polyamine. Langmuir 24:5010-5017 (Pubitemid 351725192)
80. Kamimura M, Miyamoto D, Saito Y, Soga K, Nagasaki Y (2008) Design of poly(ethylene glycol)/streptavidin co-immobilized upconversion nanophosphors and their application to fluorescence biolabeling. Langmuir 24:8864-8870
81. Kamimura M, Kanayama N, Tokuzen K, Soga K, Nagasaki Y (2011) Near-infrared (1550 nm) In vivo bioimaging based on rare-earth doped ceramic nanophosphors modified with PEG-b-poly (4-vinylbenzyl phosphonate). Nanoscale. doi:10.1039/C1NR10466G
82. Mullard A (2011) 2010 FDA drug approvals. Nat Rev Drug Discov 10:82-85